Some of the most prominent IgA nephropathy specialists in the world serve as external advisors and members of the company’s Advisory Board.

Jonathan Barratt
Professor, Department of Infection, Immunity and Inflammation, University of Leicester; Honorary Consultant Nephrologist in the John Walls Renal Unit, Leicester General Hospital, Leicester, UK
VIEW BIO
Jonathan Barratt
Professor, Department of Infection, Immunity and Inflammation, University of Leicester; Honorary Consultant Nephrologist in the John Walls Renal Unit, Leicester General Hospital, Leicester, UK

Dr. Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester and supervises a 20 strong laboratory and clinical research team focussing on basic science and translational studies in IgA nephropathy. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network.

Dr. Barratt is the Chief Investigator and on the Advisory Boards for a number of international randomised controlled clinical trials in IgA nephropathy and a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Workgroup. He is an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology, sits on the Kidney Research UK Grants Committee and a member of the Renal GeCIP (Genomics England Clinical Interpretation Partnerships) and UK Glomerulonephritis Clinical Study Group.

Holdings in Calliditas Therapeutics AB: No holdings

Daniel C. Cattran
Professor of Medicine, University of Toronto; Senior Scientist, Toronto General Research Institute, Toronto, Ontario, Canada
VIEW BIO
Daniel C. Cattran
Professor of Medicine, University of Toronto; Senior Scientist, Toronto General Research Institute, Toronto, Ontario, Canada

Dr. Cattran is a graduate of the University of Toronto Medical School. He did his postgraduate training in both Toronto, Canada and Sydney, Australia. He is currently a Professor of Medicine at the University of Toronto and a Senior Scientist at the Toronto General Research Institute. He was the principal organizer and remains the Chair of the Toronto Glomerulonephritis Registry, which currently includes over 10,000 cases of biopsy-proven glomerulonephritis. He has published over 200 articles in peer review journals and more than 30 book chapters mostly related to the natural history, outcome and treatment studies in glomerulonephritis.

Dr. Cattran has served on the editorial board of both the American Journal of Kidney Disease and the Journal of the American Society of Nephrology and has recently completed a six-year term as an associate editor for Kidney International. He is on the editorial board of Up-to-Date and is currently the author/co-author of several of their articles in glomerular disease. He has also held a number of positions in the Canadian Society of Nephrology including a term as president. He has held a number of positions within the American Society of Nephrology including two terms on the Post Graduate Education committee and was previously a member of the ASN Glomerular Disease Advisory Group.

Holdings in Calliditas Therapeutics AB: No holdings

Bengt Fellström
Senior professor at Department of Medical Sciences, Uppsala University, Uppsala, Sweden
VIEW BIO
Bengt Fellström
Senior professor at Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Dr. Fellström is currently senior professor at Uppsala University. He has authored and co-authored a large number of peer-reviewed scientific papers and presented works at many national and international conferences. Dr. Fellström, together with Dr. Roger Hällgren (Uppsala University), discovered and invented the Nefecon pharmacology principle for treatment of IgA nephropathy.

Dr. Fellström’s contributions have acclaimed recognition from honorable subject experts around the world. Dr. Fellström is actively associated with different societies and academies. His academic career is decorated with several reputed awards and funding. Dr. Bengt Fellström research interests include renal medicine, renal care and transplantation.

Holdings in Calliditas Therapeutics AB: 85,500 shares and 26 warrants of the 2015 warrant program

Jürgen Floege
Professor, head of the Department of Renal and Hypertensive Diseases, Rheumatological and Immunological Diseases (Medicine II) at the Aachen University Hospital; Director of the Department of Nephrology and Clinical Immunology at the University of Aachen, Aachen, Germany
VIEW BIO
Jürgen Floege
Professor, head of the Department of Renal and Hypertensive Diseases, Rheumatological and Immunological Diseases (Medicine II) at the Aachen University Hospital; Director of the Department of Nephrology and Clinical Immunology at the University of Aachen, Aachen, Germany

Dr. Floege is current member of the executive board of KDIGO, a society developing world-wide nephrology guidelines. He is a Distinguished Fellow of the ERA-EDTA and recipient of the 2018 ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology, immediate past-president of the German Society of Nephrology as well as incoming president of the German Society of Internal Medicine, Europe’s largest professional medical society.

Together with Professors Richard Johnson, Marcello Tonelli and John Feehally he edits the best-selling textbook “Comprehensive Clinical Nephrology”. Finally, Dr. Floege is associate editor of Kidney International since Jan 2018 and currently is a member of the editorial board of Journal of the American Society of Nephrology, Nature Reviews Nephrology, Journal of Nephrology and others. His scientific work encompasses about 550 original papers, reviews and editorials, and 40 book chapters.

Holdings in Calliditas Therapeutics AB: No holdings

Richard Lafayette
Professor of Medicine (Nephrology), the Stanford University Medical Center; Director, the Stanford Glomerular Disease Center, Stanford, California, US
VIEW BIO
Richard Lafayette
Professor of Medicine (Nephrology), the Stanford University Medical Center; Director, the Stanford Glomerular Disease Center, Stanford, California, US

Dr. Lafayette is Professor of Medicine (Nephrology) at the Stanford University Medical Center. He is the founder and director of the Stanford Glomerular Disease Center and its fellowship training program. He has a longstanding interest in glomerular disease with a focus on IgA nephropathy. This interest has led to many evaluations and some elucidation of the pathogenesis of IgA nephritis and leadership in many clinical trials. He has more than 25 years of clinical experience and has more than 125 publications including 75 peer reviewed papers. He remains passionate in efforts to discover safer and more effective treatments for patients.

Holdings in Calliditas Therapeutics AB: No holdings

Brad H. Rovin
Professor, Director of the Division of Nephrology and Vice Chairman of Medicine for Research at the Ohio State University Wexner Medical Center, Columbus, Ohio, US
VIEW BIO
Brad H. Rovin
Professor, Director of the Division of Nephrology and Vice Chairman of Medicine for Research at the Ohio State University Wexner Medical Center, Columbus, Ohio, US

Dr. Rovin is the Lee A. Hebert Distinguished Professor of Nephrology. He received his Bachelor of Science in Chemical Engineering from Northwestern University in Evanston Illinois and his Doctor of Medicine from the University of Illinois Medical School in Chicago, Illinois.

He completed a residency in Internal Medicine at Barnes Hospital in St. Louis Missouri, and a Fellowship in Nephrology at Washington University School of Medicine, St. Louis. Dr. Rovin studies the pathogenesis of glomerular diseases. His research has focused on biomarker development for glomerular diseases. He also studies experimental therapeutics in an effort to find new treatments for glomerular diseases. Dr. Rovin established a multidisciplinary Lupus, Vasculitis and Glomerulonephritis clinic and directs an advanced fellowship in autoimmune diseases for nephrologists and rheumatologists.

Holdings in Calliditas Therapeutics AB: No holdings

Vladimir Tesar
Professor, Head of the Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
VIEW BIO
Vladimir Tesar
Professor, Head of the Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Dr. Tesar is currently the head of the Department of Nephrology at the General University Hospital in Prague, in the past he also served as vice-dean at the 1st School of Medicine, Charles University in Prague. He was a member of the Council of ERA-EDTA and of its Scientific Advisory Board and currently is the chair of its Immuno-nephrology Working Group. He has authored and co-authored a large number of scientific papers and presented invited lectures at many national and international conferences. Dr. Tesar’s main areas of interest are glomerular diseases, genetic diseases of the kidney and cardiovascular complications of kidney disease.

Holdings in Calliditas Therapeutics: No holdings

Hérnan Trimarchi
Professor of Medicine, Universidad Católica Argentina; Head, Nephrology Service, Hospital Británico; Head, Kidney transplant unit, Hospital Británico, Buenos Aires, Argentina
VIEW BIO
Hérnan Trimarchi
Professor of Medicine, Universidad Católica Argentina; Head, Nephrology Service, Hospital Británico; Head, Kidney transplant unit, Hospital Británico, Buenos Aires, Argentina

Dr. Trimarchi is a former council member of the Glomerular Diseases Committee of the Buenos Aires Nephrology Association and of the Argentine Society of Nephrology. He was also member of the Scientific Committees of the Argentine Congress of Nephrology for the past fifteen years. Dr. Trimarchi is currently a member of the Steering Committee of the International IgA Nephropathy Network and Editor-in-Chief of the Journal of the Argentinian Society of Nephrology “Nefrología Argentina”. He is a Fellow of the American Society of Nephrology (FASN) and of the American College of Physicians (FACP). He is an active member of the International Society of Nephrology and of the International Society of Transplantation (IST). His PhD degree in 2010 was about the endothelium in chronic hemodialysis.

Dr. Trimarchi is a member of the editorial boards of many nephrology and transplantation journals and has written several book chapters on subjects of the endothelium, hypertension, glomerulonephritis and transplantation. He is the chief editor of the recently published book, 2017, named Glomerular Diseases, the first of its kind in the Spanish language. Dr. Trimarchi is Professor of Medicine of the Universidad Católica Argentina. His scientific work encompasses more than 15 chapters in books, 110 original papers, reviews and editorials in peer-reviewed journals, of which over 70 are indexed in PubMed.

Holdings in Calliditas Therapeutics AB: No holdings